Drug intelligence / Profile preview

capecitabine + paclitaxel

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Capecitabine + paclitaxel is a chemotherapy combination regimen used primarily for treating metastatic breast cancer. Capecitabine is an oral fluoropyrimidine carbamate prodrug that is enzymatically converted to 5-fluorouracil (5-FU) preferentially in tumor tissues. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. The combination is particularly effective because paclitaxel upregulates thymidine phosphorylase, which enhances the conversion of capecitabine to its active form.

Brand names: TaxolXeloda
Other names: IP/IV paclitaxel and oral capecitabinePaclitaxel/Capecitabine

Targets

TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on capecitabine + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + paclitaxel.

Explore the full profile